Telepharmacy medication reviews for underserved communities
Medication therapy management (MTM) combines a medicines review, patient-centred goals and agreed actions to improve medicine use, safety and wellbeing. It can reduce confusion after hospital discharge, identify adverse effects and simplify complex regimens. For Aboriginal and Torres Strait Islander patients and people with chronic conditions, that support can mean fewer avoidable contacts with emergency departments and better continuity between hospital, community and primary care. Learn more about Erupción Por Metales Níquel En Joyas Y Relojes.
The practical question is how to implement a telepharmacy service for medication therapy management in underserved communities without copying a metropolitan clinic into a video call. Australian conditions matter: medicines are commonly supplied through community pharmacies under the Pharmaceutical Benefits Scheme, while access, connectivity, workforce and reimbursement vary sharply across the country. A workable service therefore needs local co-design, explicit clinical governance and a mix of telephone, video and community-based support.
Map the access gap
Community pharmacies are often the most consistently reachable health service in places where specialist and hospital care is distant. This includes outer suburbs of Sydney and Melbourne, regional centres such as Dubbo and Broken Hill, and remote communities across Central Australia and the Northern Territory. Pharmacy teams may already see the effects of travel barriers, fragmented care and medicines that are difficult to organise.
Build the service around everyday behaviour rather than idealised attendance. Ask whether people travel by bus, work irregular shifts, share a phone, lack private space at home or need to collect repeats in person. Some value the trusted relationship built at the counter; others cannot wait in a busy shop. A needs assessment should combine local data with conversations with residents, Aboriginal Community Controlled Health Organisations, Local Health and Aboriginal Community Partnerships and Primary Health Networks.
Document the baseline before launch: travel time, missed appointments, digital access, common medication problems, referral sources and which languages are needed. Segment results by location, age, disability and service access so “underserved” is defined by measured need. This prevents a pilot from collecting mainly patients who are comfortable and well connected online.
Define safe clinical boundaries
Telepharmacy MTM is suitable for stable, non-emergent patients who can participate meaningfully from a suitable location. At booking, confirm consent, identity, current location, emergency contact and whether a family member, carer or support worker is present. Explain what can be assessed remotely, arrange a physical examination elsewhere when needed, and give clear instructions to call 000 for an emergency. Patients should know when the service cannot safely proceed.
Reconcile the actual medicines, not only the list in a referral. Ask the patient to gather packets, blister packs, a pharmacy-held list and recent discharge paperwork, and compare these with dispensing history where access permits. Record allergies, adherence and what the patient hopes to change. For suspected contact dermatitis, jewellery and watch exposure matter: this review of nickel reactions in jewellery explains one possible clue, while photographs and clinical referral guide appropriate care.
Clinical governance must reflect Australian regulation. Electronic prescriptions operate through the Commonwealth framework alongside state drugs, poisons and controlled-substances legislation, with additional controls for Schedule 4 and Schedule 8 medicines. The Privacy Act 1988 and Australian Privacy Principles, applicable state health-records laws, My Health Record consent rules and the relevant state pharmacy board’s current telepharmacy standards should all shape the workflow. Written procedures should cover documentation, prescribing authority, incident management and clinical handover.
Build a clear patient journey
Make one referral route easy for patients and referrers. Accept secure referrals from general practices, hospitals, aged-care providers, Aboriginal health services and patients themselves, with telephone or SMS assistance for people who cannot use digital forms. Explain funding clearly: Medicare funds eligible practitioner telehealth, while pharmacist MTM may be supported through state programs, accredited Home Medicines Review services, Primary Health Network funding, aged-care contracts or private fees. PBS subsidises medicines; it does not pay for the review itself.
Use a standard sequence: contact and consent, medication reconciliation, goals and preferences, recommendations, agreed actions and follow-up. The pharmacist sends a clinical report to the relevant prescriber and a plain-language action plan to the patient. Secure prescribing, repeat arrangements and pharmacy updates should be completed during the consultation where possible, then checked in a defined follow-up period. Patients who are discharged with several changes need a named contact and escalation route.
Do not make video the only doorway. Offer telephone appointments, National Interpreter Service support, Auslan interpreters and a trusted supporter when requested. Patients without home internet may use a health service, community centre or participating pharmacy with a private room. Where a pharmacy offers it, Australia Post or another participating courier can deliver medicines, reducing repeated trips to the counter.
Choose the consultation channel
No channel suits every patient. Video allows medicines to be shown and some observations made; telephone is often more private and reliable; a hybrid model supports people who need clinical examination. Offer choices during booking and document any technology failure.
| Feature | In-person MTM | Telepharmacy MTM | Hybrid MTM |
|---|---|---|---|
| Best fit | Hands-on assessment and patients comfortable travelling | Stable reviews for people unable to travel | Remote counselling with selected in-person checks |
| Patient information | Direct inspection of packs and observations | Photos, medication history and discussion | Both remote information and physical assessment |
| Examination | Blood pressure, weight and physical signs can be checked | Physical signs are limited; arrange local review | General practitioner or nurse performs selected checks |
| Privacy | A private consultation room is needed | Home privacy and connection quality vary | Remote session plus a booked private room |
| Main limits | Travel, staffing and missed appointments | Technology, identity checks and emergency limits | Coordination between services and follow-up |
A hybrid workflow often produces the best balance. The pharmacist completes the counselling and reconciliation remotely while a general practitioner, nurse or accredited home-visit service checks blood pressure, weight, swelling or other physical signs. Use the patient’s usual care team where possible, avoid duplicate tests and ensure results flow back to the pharmacist. Both parties must consent to information sharing.
Support the team and maintain quality
A telepharmacy service can become unsafe when workload, interruptions and isolation are ignored. Set limits on daily review numbers, protect uninterrupted consultation time and provide cover for sickness. Managers can use the peer-support principles in supporting pharmacy staff wellbeing to establish confidential debriefs, rotating peer contacts and escalation pathways that do not depend on one senior pharmacist being available at all hours.
Some conversations will involve addiction, severe distress, grief or suicidal thinking. Use agreed scripts and a clear boundary: assess immediate risk, involve the patient’s chosen support person where safe, and connect them with emergency or crisis services rather than attempting long-term counselling within an MTM appointment. Lifeline’s 13 11 14 line and local crisis services belong in the referral directory, with 000 reserved for immediate danger.
Quality assurance should combine human review and data. Hold a short peer case discussion after pilot clinics, sample recordings or notes with consent, compare medication recommendations between pharmacists and review every incident and near miss. Give feedback on clinical reasoning, communication and documentation. Staff should also be able to report a workload concern without it being treated as performance failure.
Recommendations for a sustainable Australian service
Build a mixed funding model before opening a permanent service. Combine public or contracted payments for eligible reviews with institutional agreements and transparent private fees, while budgeting for training, supervision, equipment, translation, interpreting and secure technology. The business case should show the cost per completed review, the proportion reaching follow-up and how equity gaps change; platform savings alone do not demonstrate clinical value.
Start with a limited pilot in one community and one clearly defined patient group. Establish referral, consent, documentation and follow-up processes before marketing the service. Review access and outcomes by community and patient characteristic so averages do not conceal groups receiving less benefit. Expand only when the team can manage demand safely.
- Co-design each pilot with local consumers, Aboriginal health services, Primary Health Networks and community pharmacies before choosing locations or hours.
- Write a one-page clinical scope covering exclusions, identity checks, consent, documentation and emergency escalation.
- Offer both telephone and video appointments, with an offline pathway rather than making connectivity a condition of care.
- Connect referrals, dispensing history, prescribing and follow-up through one accountable clinical workflow.
- Budget for training, supervision, technology, translation, Auslan interpreting and staff wellbeing, not only platform fees.
- Measure access, medication outcomes, patient understanding, equity and workforce burden after each pilot and publish the findings.
Launch with a community-defined pilot
Bring community pharmacists, prescribers, nurses, Aboriginal health representatives, aged-care staff, consumers and the relevant Primary Health Network into a launch group. Give consumers a formal role in choosing locations, hours, communication methods and outcome measures. Clear complaints, privacy and withdrawal processes should be visible at the point of booking, not buried in policy.
Make the first commitment now: select one underserved area, appoint a clinical lead and community co-chair, map local referral partners and agree on a small set of measures before accepting bookings. Fund the pilot properly, tell residents how to join and share the findings when it ends. A well-governed telepharmacy medication therapy management service can remove distance from the consultation while keeping the community at the centre of the service.